COMPARING YIELD AND COST OF FOBT AND FS IN AN AVERAGE RISK POPULATION: RESULTS AFTER 2 SCREENING ROUNDS N.Segnan MD, Ms Epi Center for Cancer Prevention.

Slides:



Advertisements
Similar presentations
ONCE-ONLY SIGMOIDOSCOPY SCREENING IN COLORECTAL CANCER SCREENING: FOLLOW UP FINDINGS OF THE ITALIAN RANDOMIZED CONTOLLED TRIAL SCORE JNCI 2011 Sep 7;103(17):
Advertisements

Implementing NICE guidance
Organized colorectal cancer screening program with FOBT: participation and diagnostic yield deteriorate with time Results – yield Aim To assess the short.
Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Spotlight on Colorectal Cancer Screening 1 1. Home Screening for Colon Cancer
Surveillance colonoscopy after polypectomy – how frequent? Dr Chu Ming Leong Tuen Mun Hospital 1.
Update on Screening of Gastrointestinal Diseases Niraj Jani, M.D. Greater Baltimore Medical Center 1/30/15.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
HOW STANDING ORDERS HELPED US IMPROVE CANCER SCREENING: REPORT FROM A NEW PPRNet MEMBER JULIO A SAVINON, MD RIO GRANDE MEDICINE INC. HARLINGEN, TX.
COLONOSCOPY VERSUS FECAL IMMUNOCHEMICAL TESTING IN COLORECTAL-CANCER SCREENING The New England Journal of Medicine february 23, 2012.
Sex Differences in the Prevalence and Correlates of Colorectal Cancer Testing: Health Information National Trends Survey Sally W. Vernon 1, Amy.
CCE 4: Bridging Clinical Expertise Using Predictive Computational Cancer Models CRC screening and follow-up – Semi-mechanistic model of CRC development.
DR Jameel Tariq Miro.  Lifetime incidence 5%  90% of cases occur after age 50  One-third of patients with colorectal cancer die from the disease 
Colorectal Cancer Screening John Pelzel MD Sleepy Eye Medical Center.
Joint Hospital Surgical Grand Round 19 June 2004.
Haley Hyde Jessica Fordham Jena Hamm  Colorectal cancer is a leading cause of cancer related deaths every year.  150,000 Americans will be diagnosed.
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
Bowel Screening in Scotland – Current Challenges and Possible Solutions Prof. Bob Steele Ninewells Hospital, University of Dundee.
AIMGP Seminar Series January 2004 Joo-Meng Soh Edited by Gloria Rambaldini CANCER SCREENING PART II.
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
High risk population in GI field how we can find them? Ahmad Shavakhi MD Associate professor of gastroenterology.
Colonoscopy; Surveillance Indications
TREATMENT OF LARGE AND GIANT COLORECTAL POLYPS IN THE REAL WORLD UEGW, PARIS, 2007 Association pour le Dépistage du Cancer colorectal dans le Haut-Rhin.
FIRST TWO AND HALF YEAR OF NATIONAL SCREENING PROGRAM FOR COLORECTAL CANCERS IN REPUBLIC CROATIA Miroslava Katicic 1, Milan Kujundzic 2, Davor Stimac 3,
Gender differences in colorectal cancer screening, attitudes and information preferences Joan M. Griffin, PhD Greta Friedemann-Sánchez, PhD Diana Burgess,
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
Results and cost of a population-based biennial faecal occult blood colorectal cancer screening program Bernard DENIS, Philippe PERRIN, Jean François VIES,
Colorectal Screening NZ Bowel Screening Pilot. WHO Screening criteria  Impt Health condition  Identifiable Latent or early stage  Understand natural.
INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.
Population Screening for Colorectal Cancer - update of evidences
Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based fecal occult blood testing: a population-based controlled trial.
PREPARED BY Colorectal Cancer Programme Screening for Colorectal Cancer A/P Susan Parry, Gastroenterologist, CD MOH Bowel Cancer Programme.
A National Bowel Screening Programme Anticipated Colonoscopy Volumes Susan Parry Gastroenterologist, Clinical Director, MOH Bowel Cancer Programme Emmanuel.
Brian Cox Research Associate Professor: Cancer epidemiology and screening University of Otago Hugh Adam Cancer Epidemiology Unit Department of Preventive.
The effects of inadequate preparation quality for colonoscopy Eric Sherer and Michael Catlin August 20 th, 2010 HSR&D Work-in-Progress 1.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Organizing Colorectal Cancer.
Screening for Colorectal Cancer (CRC) Nov, 2007 A Aljebreen, FRCPC Division of Gastroenterology KKUH, Riyadh.
Prevalence of Dry Eye Disease among Elderly Korean Population Sang Beom Han, MD, 1 Joon Young Hyon, MD, 1 Won Ryang Wee, MD, 2,3 Jin Hak Lee, MD, 1, 3.
Yield of colonoscopy for advanced neoplasia in a population-based setting Bernard DENIS, Jacques PICOT, Jean François VIES, Marjorie MUSSO, Paul François.
Senior Statistician Per-Henrik Zahl, MA MD PhD
MALIGNANT POLYPS DURING THE FIRST THREE SCREENING ROUNDS ( ) FOR COLON-RECTAL CANCER (CRC) IN A NORTH-EASTERN SANITARY DISTRICT (ULSS-1 VENETO).
Do all colorectal polyps require pathological examination? Aim To assess whether it is possible to omit the pathological examination of some polyps without.
Flexible Sigmoidoscopy And Whole Colon Imaging In The Diagnosis Of Cancer In Patients With Colorectal Symptoms Peter O’Leary Journal Club 13/10/08.
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
BC Cancer Agency CARE & RESEARCH Breast Cancer Mortality After Screening Mammography in British Columbia Women Andrew J. Coldman, Ph.D. Norm Phillips,
Colorectal Cancer Screening Implementation of a public health programme An Expert Group on Colorectal Cancer Screening Cancer Society of Finland, Finnish.
First results of a pilot population-based faecal occult blood colorectal cancer screening program B. DENIS, P. PERRIN, J.F. EBELIN, P. WEBER, E. KALTENBACH,
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Hereditary Colorectal Cancer:
DIABETES AS A RISK FACTOR FOR COGNITIVE DECLINE IN OLDER PATIENTS F. Limongi, A. Marseglia, S. Maggi, M. Noale, G. Romanato, P. Siviero, G. Crepaldi CNR,
GASTROINTESTINAL ENDOSCOPY Volume 78, No. 3 : 2013 F1 김태영
Am J Gastroenterol 2012; 107:1213– June 2012 R3. 김동희 /prof. 이창균.
Hearing Aid Use and Perceived Hearing Handicap in Older Adults
Presented by Liana Poghosyan, MD Ne Moe, MD May 19, 2008
1University of Kentucky, Lexington, Kentucky
بسم الله الرحمن الرحيم.
Colorectal Cancer Screening Guidelines
More Ontarians need to be screened for colorectal cancer (Sept. 2012)
Bowel cancer screening update GP education event 28 Nov 2017
Full-Spectrum Endoscopy Improves Adenoma Detection Compared to Conventional Colonoscopy PLUS Right-Colon Examination With Scope Retroflexion: A Randomized,
Evaluation of a Spiritually-based Intervention to Increase Colorectal Cancer Knowledge and Screening Among Church-attending African Americans and Whites.
Volume 147, Issue 5, Pages e1 (November 2014)
Hereditary Colorectal Cancer: From Genetic Testing to Prevention
Trends in Colorectal Cancer Screening Among Maryland Residents Age 65 and Older Maryland Cancer Survey, Presented by: Carolyn Poppell, MS University.
Common indicators related to organization and invitation
Bowel Screening in Wales
Volume 147, Issue 5, Pages e1 (November 2014)
Reporting in CRC screening
Risks of interval colorectal cancer in a FIT-based screening program
Presentation transcript:

COMPARING YIELD AND COST OF FOBT AND FS IN AN AVERAGE RISK POPULATION: RESULTS AFTER 2 SCREENING ROUNDS N.Segnan MD, Ms Epi Center for Cancer Prevention (CPO Piemonte) and S. Giovanni Battista Hospital. Torino (Italy) Ottawa May 10-12, 2006 IBSN Biennial Meeting

SCORE2 N. Segnan CPO 2006

AIMS (1) N. Segnan CPO 2006 a)a) To estimate compliance and coverage adopting different screening strategies b) To compare Detection Rate of different tests (first test, subsequent tests and follow-up) and to estimate screening impact on CRC incidence and mortality c) To estimate costs of different strategies d) To define quality indicators of the screening programme

POPULATION Males and females aged 55 to 64 years of age EXCLUSION CRITERIA Previous CRC, polyps, IBD Endoscopy within previous 2 years 2 first degree relatives with CRC Severe disease Severe psychiatric symptoms N. Segnan CPO 2006

EXCLUDED* 553 TORINO 84 GPs MILANO 30 GPs FIRENZE 36 GPs BIELLA 19 GPs RIMINI 21 GPs PATIENTS (AGE 55-64) PATIENTS (AGE 55-64) 2923 ELIGIBLE 2639 PATIENTS (AGE 55-64) 5333 GP SAMPLE EXCLUDED* 352 EXCLUDED* 220 EXCLUDED* 228 EXCLUDED* 284 RESIDENTS AGED 55 TO 64 IN SELECTED DISTRICTSTS ELIGIBLE STUDY POPULATION PATIENTS (AGE 55-64) 3025 PATIENTS (AGE 55-64) 3359 ELIGIBLE ELIGIBLE 4981 ELIGIBLE 2805 ELIGIBLE 3131 Source sampling by study center - Fig. 1 Segnan et al. Journal of the National Cancer Institute 2005; 97(5) N. Segnan CPO 2005

SCREENING TEST - FOBT IMMUNOLOGICAL TEST (Immunodia- HempSp- Fujirebio. Inc Tokio,Japan) AUTOMATED READING IN A CENTRAL LABORATORY N. Segnan CPO 2006

SCREENING PROCEDURE - FS SCREENING TEST Flexible sigmoidoscopy : Scope advanced beyond the sigmoid-descending colon junction (complete test).Polyps < 10 mm removed during FS cold-snare technique recommended for polyps < 6 mm BOWEL PREPARATION: Single enema (133 ml sodium-phosphate) self-administered 2 hours before the test. N. Segnan CPO 2006

REFERRAL FOR COLONOSCOPY 1 distal polyp >= 10 mm >=3 adenomas < 10 mm 1 high risk (severe dysplasia or cancer, villous histology) adenoma < 10 mm N. Segnan CPO 2006

INTERVENTIONS BIENNIAL FOBT “ONCE-ONLY” SIGMOIDOSCOPY PATIENTS’ CHOICE SIGMOIDOSCOPY + BIENNIAL FOBT (PATIENTS WITH NEGATIVE FS) N. Segnan CPO 2006

TOTAL yrs SCREENING ARM invited attended (%) FOBT by mail (30.1) FOBT by GP or screening facility (28.1) Once-only sigmoidoscopy (28.1) Sigmoidoscopy + biennial FOBT (28.1) Patient’s choice 3579 FOBT 522 (14.6) Sigmoidoscopy 448 (12.5) Total 970 (27.1) TOTAL (28.1) N. Segnan CPO 2005 Participation rate by sex, age, and screening arm (undelivered invitations are excluded from the denominator) (2) Segnan et al. Journal of the National Cancer Institute 2005; 97(5)

nOR* (95% CI) ALL PATIENTS EXAMINED (excluding those in patient’s choice arm) FOBT arms (referent) Sigmoidoscopy arms ( ) yrs (referent) yrs ( ) Women (referent) Men ( ) N. Segnan CPO 2005 Odds ratio for advanced adenomas in FOBT and sigmoidoscopy arms by age and sex and among all patients examined, excluding those in the patient’s choice arm, by age, sex, and screening test (2) Segnan et al. Journal of the National Cancer Institute 2005; 97(5) * Multivariable ORs adjusted for screening center and for all the other variables in the table

N = N. Segnan CPO 2006 The study has been enlarged…..

INTERVENTIONS BIENNIAL FOBT (17,730) “ONCE-ONLY” SIGMOIDOSCOPY (5,057) (PATIENTS’ CHOICE) stopped SIGMOIDOSCOPY + BIENNIAL FOBT (PATIENTS WITH NEGATIVE FS) (20,414) N. Segnan CPO 2006

17730invited 4599 (25.9%)Attenders (1 st screening round) 5837 (32.9%)Attenders (at least 1 invitation over 2 screening rounds) N. Segnan CPO 2006 FOBT – compliance

5057Invited 1405(28%)Attenders N. Segnan CPO 2006 FS once only - compliance

20414Invited 5689(27.9)Attenders - FS 5192Invited after 2 years – FOBT 3220(62%)Attenders - FOBT N. Segnan CPO 2006 FS + FOBT - compliance

CCRAAD 1 test: 1 st or 2 nd round N. TESTS POSITIVE215 (3.7%)0.29%1.21% PPV40.9% 2 nd test (1 st neg.) TESTS POSITIVE112 (3.3%)0.09%0.86% PPV28.6% at least 1 test (over 2 rounds) PATIENTS POSITIVE327 (5.6%)0.34%1.71% PPV36.7% N. Segnan CPO 2006 FOBT – Detection Rates

CCRAAD 1 st testDISTALPROXIMALDISTALPROXIMAL N. TESTS POSITIVE164 (3.6%)0.24%0.11%1.04%0.20% PPV44.5% 2 nd test (1 st neg.) TESTS POSITIVE112 (3.3%)0.06%0.03%0.65%0.21% PPV28.6% 1 st test (2 nd round) TESTS POSITIVE51 (4.1%)0.0%0.1%0.8%0.3% PPV29.4% at least 1 test (over 2 rounds) PATIENTS POSITIVE327 (5.6%)0.22%0.12%1.37%0.34% PPV36.7% N. Segnan CPO 2006 FOBT – Detection Rates

CCRAAD 1 st testDISTALPROXIMALDISTALPROXIMAL FS TESTS %0.04%4.74%0.13% subsequent tests FOBT TESTS POSITIVE %0.12%0.22%0.31% total %0.11%4.87%0.3% N. Segnan CPO 2006 FS + FOBT - Detection Rates

CCRAAD DISTPROXDISTPROX FS TESTS DR %0.36%0.00%5.65%0.07% N. Segnan CPO 2006 FS once-only - Detection Rate

Detection rate by screening arm PATIENTSn CRC % n AAD % Total % FOBT,2 rounds invit FS + FOBT FS

Detection rate by intention to treat Invitedn CRC % n AAD % Total % FOBT,2 rounds invit FS + FOBT FS

ADVANCED ADENOMAS DETECTION RATES PER 1000 BY AGE AND GENDER

COST FS: 132 $ FOBT: 37$ The cost includes the assessment (referral to colonoscopy, histology …) and the organization

Cost per Detected Lesion

After 2 FOBT screening rounds, the cumulative yield of advanced adenomas was about one third for FOBT compared to FS, while CRC yield was similar. The participation to FOBT (in the screening programs recently started in the study areas attendance is above 40%) might influence the estimates of the relative difference in neoplasia yield. N. Segnan CPO 2006 Conclusions 1

*At the prevalent round: -the cost per detected CRC is lower for FOB Test than for FS -the cost per detected AAD is higher for FOB Test than for FS * after 2 FOB Tests, the cost per detected lesion is higher both for CRC and for AAD compared to FS * The detetection rate of AAD is the same at years and at years both in men and in women, supporting the observation of a plateau of prevalence of AAD around 60 years N. Segnan CPO 2006 Conclusions 2

Carlo Senore CPO Piemonte, Torino Bruno Andreoni, Surgery Unit, European Institute of Oncology, Milano, Luigi Bisanti, Epidemiology Unit. ASL "Citta' di Milano", Milano, Guido Castiglione, Gastroenterology Unit, CSPO, Firenze, Arnaldo Ferrari, Gastroenterology Unit, Maria Vittoria Hospital, Torino, Alberto Foco, Gastroenterology Unit, S Giovanni AS Hospital, Torino, Stefano Gasperoni, Gastroenterology Unit, Infermi Hospital, AUSL Rimini, Rimini, Giuseppe Malfitana, Gastroenterology Unit, Infermi Hospital, ASL 12, Biella, Angelo Pera, Gastroenterology Unit, Mauriziano "Umberto I" Hospital, Torino, Serafino Recchia, Gastroenterology Unit, S Giovanni Bosco Hospital, Torino, Mario Rizzetto, Gastroenterology Unit, S Giovanni Battista-Molinette Hospital, Torino, Marco Zappa, CSPO, Firenze, Italy